Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


4th International Conference on Cardiovascular Diseases and Therapeutics

Prague, Czech Republic

Eyubova Ulviyya

Eyubova Ulviyya

Azerbaijan Medical University, Azerbaijan

Title: Drug and Cost Compere Analysis for treatment of Chronic Heart Failure


Biography: Eyubova Ulviyya


Background: Currently, the use of many new medications and device treatments has been started to treat patients with chronic heart failure. Modern principles of current treatment techniques are based on the pathogenic concept that develops as a result of the long-term activation of the CHF neurohormonal system. At present, the inhibitor of neprilysin is widely used in the treatment of CHF in the world practice.

In addition to the medical treatment of CHF, device treatments have also developed significantly in modern times. Being one of them, in recent years the resynchronous therapy of the heart is one of the most widely used treatments over the world.

Purpose: Our study has been conducted in the form of 2 groups. The first group consists of the patients treated with complex medical therapy including sacubitril / valsartan. And the second group consists of the patients implanted a device for resynchronous therapy of the heart. Our aim is to assess the changes in the clinical indicators in both groups after 6 months.

Methods: The results of 64 male and female with CHF were researched. Patients were over 38 years of age. Eligibility criteria included a history of chronic heart failure, circulatory failure (functional class II-IV, NHYA) and a left ventricular ejection fraction of less than 40%. Exclusion criteria included acute myocardial infarction, hypertrophic cardiomyopathy, congenital heart defects, patients under 25 years of age, heart failure in oncological patients.

Results: At the time of re-examination after 6 months, there is a high positive change in the clinical indicators of patients, functional classes and ejection fraction of left ventricul in first group than second group.

Conclusion: The results of both treatments have been compared both medically and economically. In results, full patogenetic treatment (including sacubitril/valsartan) gave better results.